Weekly Respiratory Research Analysis
This week’s respiratory literature highlights converging mechanistic and clinical advances: a Cell Reports mechanistic study identifies CEPT1 deficiency linking epithelial lipid imbalance to ER stress and mitochondrial dysfunction in asthma, revealing a new therapeutic axis; a pair of large randomized trials led to Lancet publication showing ST2/IL‑33 blockade (astegolimab) reduces COPD exacerbations independent of eosinophil counts, opening a new biologic option; and a Nature Communications pap
Summary
This week’s respiratory literature highlights converging mechanistic and clinical advances: a Cell Reports mechanistic study identifies CEPT1 deficiency linking epithelial lipid imbalance to ER stress and mitochondrial dysfunction in asthma, revealing a new therapeutic axis; a pair of large randomized trials led to Lancet publication showing ST2/IL‑33 blockade (astegolimab) reduces COPD exacerbations independent of eosinophil counts, opening a new biologic option; and a Nature Communications paper demonstrates ventrolateral medullary astrocytes actively modulate sigh‑linked arousals under hypoxia, advancing our understanding of respiratory–arousal circuitry with translational implications.
Selected Articles
1. FOXA1-mediated CEPT1 deficiency in airway epithelium drives asthma via an ER stress-mitochondrial dysfunction axis.
This mechanistic study identifies CEPT1 downregulation in asthmatic airway epithelium as causing phospholipid imbalance, activation of all three ER stress branches, ER Ca2+ disruption, and mitochondrial dysfunction. A FOXA1–CEPT1 regulatory axis links epithelial lipid metabolism to stress responses and inflammation, suggesting therapeutic strategies to restore phosphatidylcholine balance or target ER/mitochondrial resilience.
Impact: Uncovers a novel epithelial lipid–ER–mitochondria mechanistic axis explaining epithelial dysfunction in asthma and nominates CEPT1 as a potential therapeutic target and biomarker for precision approaches.
Clinical Implications: Supports development of therapies that restore phosphatidylcholine balance, upregulate CEPT1, or mitigate ER stress/mitochondrial injury; CEPT1 expression could stratify patients for targeted interventions in translational studies.
Key Findings
- CEPT1 is significantly downregulated in asthmatic airway epithelium.
- CEPT1 deficiency reduces PC/PE, induces phospholipid imbalance, activates all three ER stress branches, and disrupts ER Ca2+ homeostasis.
- Associated mitochondrial dysfunction links epithelial metabolic defects to asthma pathophysiology.
- FOXA1 regulates CEPT1, establishing a FOXA1–CEPT1 mechanistic axis.
2. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.
Two large randomized, double‑blind, placebo‑controlled trials showed astegolimab (anti‑ST2) reduced annualized moderate/severe COPD exacerbations versus placebo, with balanced safety. Efficacy signals were seen across eosinophil strata, supporting ST2/IL‑33 pathway blockade as a new biologic approach for frequent‑exacerbator COPD patients.
Impact: One of the first large eosinophil‑agnostic biologic programs in COPD demonstrating exacerbation reduction, potentially changing therapeutic options for a population with limited biologic choices.
Clinical Implications: Pending regulatory approval and biomarker refinement, astegolimab could be offered as add‑on biologic therapy for COPD patients with frequent exacerbations regardless of blood eosinophil counts, warranting integration into exacerbation‑reduction strategies.
Key Findings
- ALIENTO: astegolimab Q2W reduced annualized moderate/severe exacerbations vs placebo (rate ratio 0.85; p=0.049).
- ARNASA: astegolimab Q4W reduced exacerbations vs placebo (rate ratio 0.82; p=0.024).
- Adverse events and mortality were balanced across groups, supporting an acceptable safety profile.
3. Astrocyte activation in the ventrolateral medulla modulates breathing and arousal states.
In alert mice, Aldh1l1‑positive astrocytes in the ventral respiratory column activate prior to sighs and are recruited by hypoxia; opto/chemogenetic activation increases arousals coupled with sighs and enhances calcium transients in nearby catecholaminergic neurons. The study identifies an astrocyte–neuronal mechanism for hypoxia‑evoked ventilatory and arousal responses.
Impact: Identifies astrocytes as causal modulators of sigh‑linked arousal and hypoxia responses, advancing cellular circuit knowledge with implications for disorders of arousal and breathing control.
Clinical Implications: Suggests new avenues to modulate arousal and ventilatory responses pharmacologically or circuit‑targeted in conditions such as sleep‑disordered breathing, neonatal hypoxia vulnerability, or impaired arousal syndromes.
Key Findings
- A subset of Aldh1l1 astrocytes in the ventral respiratory column activates prior to sigh generation and is recruited by hypoxia.
- Chemogenetic/optogenetic activation of these astrocytes increases arousal probability coupled with sighs.
- Astrocyte activation enhances calcium transients in nearby catecholaminergic neurons immediately before arousal‑with‑sigh events.